David Schwimmer, MD
Gastroenterology · Palm Beach Gardens, FLNPI 1245641380
Payments from drug & device makers
Across 421 payments — averaging $57.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$834
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$624
- Bristol Myers Squibb$417
- QOL Medical, LLC$407
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$13,77557%
- Travel & lodging$4332%
- Food & beverage$9,60340%
- Education$3892%
- Gifts$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 138 | $17,793 |
| Johnson & Johnson | 65 | $1,562 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $834 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $624 |
| Bristol Myers Squibb | 21 | $417 |
| QOL Medical, LLC | 21 | $407 |
| Intercept Pharmaceuticals, Inc. | 12 | $288 |
| Pfizer | 13 | $250 |
| Sanofi | 8 | $220 |
| Nestle Healthcare Nutrition Inc. | 8 | $171 |
| Ironwood Pharmaceuticals, Inc | 8 | $170 |
| Janssen Scientific Affairs, LLC | 2 | $158 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| Braintree Laboratories, Inc. | 8 | $140 |
| Redhill Biopharma Inc. | 9 | $138 |
| Olympus America Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| Evoke Pharma, Inc. | 5 | $71 |
| Daiichi Sankyo Inc. | 3 | $71 |
| Lilly USA, LLC | 3 | $60 |
| Merck | 3 | $60 |
| Boston Scientific | 1 | $59 |
| Palette Life Sciences, Inc. | 1 | $59 |
| Phathom Pharmaceuticals, Inc. | 2 | $49 |
| Fresenius Kabi USA, LLC | 2 | $45 |
| Ardelyx, Inc. | 3 | $44 |
| UCB, Inc. | 2 | $40 |
| Vivus LLC | 2 | $35 |
| Gilead | 1 | $32 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Amgen | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| AstraZeneca | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$8,944
- Rinvoq$6,508
- Tremfya$354
- DISPOSABLE TRIPLE LUMEN SPHINCTEROTOME$125
- Single Use Electrosurgical Knife KD-655$125
- STELARA$125
- Entyvio$122
How this compares
$24,282 in reported general payments places this provider in the 80th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $349,315 |
| Humira(Cf) PenAdalimumab | 26 | $231,636 |
| CreonLipase/Protease/Amylase | 12 | $33,010 |
| MounjaroTirzepatide | 15 | $16,019 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 40 | $6,841 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 45 | $6,514 |
| Pantoprazole Sodium | 229 | $4,265 |
| CholestyramineCholestyramine (With Sugar) | 26 | $1,339 |
| Colestipol Hcl | 25 | $1,125 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 12 | $758 |
| Ondansetron OdtOndansetron | 12 | $178 |
| Omeprazole | 29 | $146 |
| Rabeprazole Sodium | 12 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,562 | $349,31513 claims |
| AbbVieCreon | $17,793 | $33,01012 claims |
| Lilly USA, LLCMounjaro | $60 | $16,01915 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $18 | $6,84140 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $624 | $6,51445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Palm Beach Gardens
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
- Henry LevineOrlando$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.